BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 17537758)

  • 1. FDG-PET/CT in restaging of patients with recurrent breast cancer: possible impact on staging and therapy.
    Veit-Haibach P; Antoch G; Beyer T; Stergar H; Schleucher R; Hauth EA; Bockisch A
    Br J Radiol; 2007 Jul; 80(955):508-15. PubMed ID: 17537758
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of 2-[18F] fluoro-2-deoxy-D-glucose-positron emission tomography/computed tomography in the post-therapy surveillance of breast cancer.
    Chang HT; Hu C; Chiu YL; Peng NJ; Liu RS
    PLoS One; 2014; 9(12):e115127. PubMed ID: 25517451
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Accuracy of whole-body dual-modality fluorine-18-2-fluoro-2-deoxy-D-glucose positron emission tomography and computed tomography (FDG-PET/CT) for tumor staging in solid tumors: comparison with CT and PET.
    Antoch G; Saoudi N; Kuehl H; Dahmen G; Mueller SP; Beyer T; Bockisch A; Debatin JF; Freudenberg LS
    J Clin Oncol; 2004 Nov; 22(21):4357-68. PubMed ID: 15514377
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Is combined 18F-fluorodeoxyglucose-positron emission tomography/computed tomography superior to positron emission tomography or computed tomography alone for diagnosis, staging and restaging of pancreatic lesions?
    Casneuf V; Delrue L; Kelles A; Van Damme N; Van Huysse J; Berrevoet F; De Vos M; Duyck P; Peeters M
    Acta Gastroenterol Belg; 2007; 70(4):331-8. PubMed ID: 18330088
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison between 18F-FDG PET, in-line PET/CT, and software fusion for restaging of recurrent colorectal cancer.
    Kim JH; Czernin J; Allen-Auerbach MS; Halpern BS; Fueger BJ; Hecht JR; Ratib O; Phelps ME; Weber WA
    J Nucl Med; 2005 Apr; 46(4):587-95. PubMed ID: 15809480
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Combined FDG PET/CT imaging for restaging of colorectal cancer patients: impact of image fusion on staging accuracy].
    Strunk H; Bucerius J; Jaeger U; Joe A; Flacke S; Reinhardt M; Hortling N; Palmedo H
    Rofo; 2005 Sep; 177(9):1235-41. PubMed ID: 16123869
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Staging pathways in recurrent colorectal carcinoma: is contrast-enhanced 18F-FDG PET/CT the diagnostic tool of choice?
    Soyka JD; Veit-Haibach P; Strobel K; Breitenstein S; Tschopp A; Mende KA; Lago MP; Hany TF
    J Nucl Med; 2008 Mar; 49(3):354-61. PubMed ID: 18287263
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The role of FDG PET/CT in patients with locoregional breast cancer recurrence: a comparison to conventional imaging techniques.
    Aukema TS; Rutgers EJ; Vogel WV; Teertstra HJ; Oldenburg HS; Vrancken Peeters MT; Wesseling J; Russell NS; Valdés Olmos RA
    Eur J Surg Oncol; 2010 Apr; 36(4):387-92. PubMed ID: 19962268
    [TBL] [Abstract][Full Text] [Related]  

  • 9. TNM staging with FDG-PET/CT in patients with primary head and neck cancer.
    Veit-Haibach P; Luczak C; Wanke I; Fischer M; Egelhof T; Beyer T; Dahmen G; Bockisch A; Rosenbaum S; Antoch G
    Eur J Nucl Med Mol Imaging; 2007 Dec; 34(12):1953-62. PubMed ID: 17717661
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Whole-body dual-modality PET/CT and whole-body MRI for tumor staging in oncology.
    Antoch G; Vogt FM; Freudenberg LS; Nazaradeh F; Goehde SC; Barkhausen J; Dahmen G; Bockisch A; Debatin JF; Ruehm SG
    JAMA; 2003 Dec; 290(24):3199-206. PubMed ID: 14693872
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Integrated contrast-enhanced diagnostic whole-body PET/CT as a first-line restaging modality in patients with suspected metastatic recurrence of breast cancer.
    Dirisamer A; Halpern BS; Flöry D; Wolf F; Beheshti M; Mayerhoefer ME; Langsteger W
    Eur J Radiol; 2010 Feb; 73(2):294-9. PubMed ID: 19181468
    [TBL] [Abstract][Full Text] [Related]  

  • 12. FDG-PET/CT in the diagnosis of recurrent breast cancer.
    Murakami R; Kumita S; Yoshida T; Ishihara K; Kiriyama T; Hakozaki K; Yanagihara K; Iida S; Tsuchiya S
    Acta Radiol; 2012 Feb; 53(1):12-6. PubMed ID: 22067206
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A prospective diagnostic accuracy study of 18F-fluorodeoxyglucose positron emission tomography/computed tomography, multidetector row computed tomography, and magnetic resonance imaging in primary diagnosis and staging of pancreatic cancer.
    Kauhanen SP; Komar G; Seppänen MP; Dean KI; Minn HR; Kajander SA; Rinta-Kiikka I; Alanen K; Borra RJ; Puolakkainen PA; Nuutila P; Ovaska JT
    Ann Surg; 2009 Dec; 250(6):957-63. PubMed ID: 19687736
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Detection and restaging of residual and/or recurrent nasopharyngeal carcinoma after chemotherapy and radiation therapy: comparison of MR imaging and FDG PET/CT.
    Comoretto M; Balestreri L; Borsatti E; Cimitan M; Franchin G; Lise M
    Radiology; 2008 Oct; 249(1):203-11. PubMed ID: 18710963
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical value of manual fusion of PET and CT images in patients with suspected recurrent colorectal cancer.
    Nakamoto Y; Sakamoto S; Okada T; Senda M; Higashi T; Saga T; Togashi K
    AJR Am J Roentgenol; 2007 Jan; 188(1):257-67. PubMed ID: 17179375
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Performance of integrated FDG-PET/contrast-enhanced CT in the staging and restaging of colorectal cancer: comparison with PET and enhanced CT.
    Dirisamer A; Halpern BS; Flöry D; Wolf F; Beheshti M; Mayerhoefer ME; Langsteger W
    Eur J Radiol; 2010 Feb; 73(2):324-8. PubMed ID: 19200683
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Utility of 2-[18F] fluoro-2-deoxy-D-glucose positron emission tomography and positron emission tomography/computed tomography imaging in the preoperative staging of head and neck squamous cell carcinoma.
    Roh JL; Yeo NK; Kim JS; Lee JH; Cho KJ; Choi SH; Nam SY; Kim SY
    Oral Oncol; 2007 Oct; 43(9):887-93. PubMed ID: 17207656
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Advantages and limitations of FDG PET in the follow-up of breast cancer.
    Lind P; Igerc I; Beyer T; Reinprecht P; Hausegger K
    Eur J Nucl Med Mol Imaging; 2004 Jun; 31 Suppl 1():S125-34. PubMed ID: 15085295
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative study of FDG PET/CT and conventional imaging in the staging of rhabdomyosarcoma.
    Tateishi U; Hosono A; Makimoto A; Nakamoto Y; Kaneta T; Fukuda H; Murakami K; Terauchi T; Suga T; Inoue T; Kim EE
    Ann Nucl Med; 2009 Feb; 23(2):155-61. PubMed ID: 19225939
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Restaging of recurrent cervical carcinoma with dual-phase [18F]fluoro-2-deoxy-D-glucose positron emission tomography.
    Lai CH; Huang KG; See LC; Yen TC; Tsai CS; Chang TC; Chou HH; Ng KK; Hsueh S; Hong JH
    Cancer; 2004 Feb; 100(3):544-52. PubMed ID: 14745871
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.